Axial arthritis of the spine
Conditions
Interventions
Group 1:Adequate adamuzumab dose for 52 weeks
Group 2:Adequate dosage of adamuzumab for 12 weeks
Group 3:Use NSAIDs, csDMARDs or other oral medications
Sponsors
The Second Affiliated Hospital of Guangxi Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Aged >=18 years; 2. In line with the 2009 International Spondyloarthritis Association (ASAS) axSpA classification criteria; 3. Non-steroidal anti-inflammatory drugs alone or other local treatment drugs have poor control effect or intolerance.
Exclusion criteria
Exclusion criteria: 1. Received other biological agents and targeted drug therapy in the past; 2. Those who are in the period of systemic acute or chronic infection, or have a history of active tuberculosis in the past; 3. Malignant tumor; 4. Moderate to severe heart failure (New York Heart Association grade 3-4); 5. Pregnant women and lactating women; 6. Those who are allergic to adalimumab components.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| blood routine examination;urine routine examination;C-reactive protein;Blood sedimentation;CT of sacroiliac joint;MRI of sacroiliac joint; | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes in PROs at each follow-up point compared to baseline;Changes in disease activity at each follow-up point compared with baseline; | — |
Countries
China
Contacts
Public ContactLi Meiling
The Second Affiliated Hospital of Guangxi Medical University
Outcome results
None listed